drugset / Trial / NCT07553065

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

NCT07553065

Phase 2 Not yet recruiting 210 enrolled Vensica Therapeutics Ltd. TFS Trial Form Support · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This Phase 2b study is a prospective, multicenter, double blind, randomized, placebo and sham controlled trial to assess the safety, efficacy and dose response of NT 201 delivered by the Vibe System in participants with idiopathic overactive bladder (OAB).

Timeline

Start
2026-07
Primary completion
2027-09
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 200 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 300 iu Other

Indications